News | Molecular Imaging | July 05, 2023

NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer 

NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Nucleus RadioPharma, a full-service Contract Development and Manufacturing Organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies, today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225(Ac-225). Under terms of the agreement, NorthStar will supply its high purity, non-carrier added (n.c.a.) Ac-225 to Nucleus. Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. 

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. Clinical research and commercial use of Ac-225 have been constrained by chronic short supply due to limitations of current production technology. NorthStar is positioned to be the first commercial-scale producer of n.c.a. Ac-225 and copper-67 (Cu-67) for advancing clinical research and commercial radiopharmaceutical therapy products. The Company will use its electron accelerator technology to produce n.c.a. Ac-225 that is free of long-lived radioactive contaminants and byproducts associated with other production methods. Such contaminants pose regulatory and waste management challenges for pharmaceutical companies, hospitals, and health systems. 

“NorthStar is applying the same development expertise to rapidly advance large-scale production of n.c.a. Ac-225 that has positioned us at the forefront of U.S. radioisotope production as the only national commercialized producer of the important medical radioisotope molybdenum-99 (Mo-99), and we previously announced successful production of Mo-99 using electron accelerator technology,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes. “Progress on our dedicated, state-of-the-art Actinium-225 Production facility is on schedule. The electron accelerator is installed and initial production of radiochemical grade Ac-225 is planned in 2024. NorthStar expects to submit a Drug Master File to the FDA as quickly as possible, which, upon acceptance by the FDA, will allow NorthStar to provide cGMP grade Ac-225. We are very pleased to enter this Ac-225 supply agreement with Nucleus RadioPharma, and we look forward to working with them in their efforts to provide targeted alpha radioligand therapies for patients with cancer.” 

“Nucleus was established to address the acute manufacturing scarcity of radionuclides and theranostics, which poses significant challenges to patient care and clinical trials for new radiopharmaceuticals,” said Charles S. Conroy, Chief Executive Officer of Nucleus. “We are pleased to work with NorthStar as an experienced and reliable partner in innovative, accelerator-based radioisotope production technology, and to using its n.c.a. Ac-225 to develop highly transformative treatments for patients with cancer.” 

For more information: 


Related Radioisotope Content: 

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones 

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)   

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)     

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal     

Update on Unplanned Outage of the HFR Reactor     

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply     

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals     

How Nuclear Fusion is Revolutionizing Medical Isotope Production     

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes     

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE     

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m 

Related Content

News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
News | Quality Assurance (QA)

November 25, 2023 — Mirion announced that it will debut the new Instadose VUE personal dosimeter, from its Dosimetry ...

Time November 25, 2023
News | Contrast Media

November 13, 2023 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a pioneer in diagnostic ...

Time November 13, 2023
News | PET Imaging

November 8, 2023 — In a small study, researchers at the National Institutes of Health have found that positron emission ...

Time November 08, 2023
News | PET Imaging

November 6, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the National Institute ...

Time November 06, 2023
News | Linear Accelerators

October 25, 2023 — A new order for several Elekta Harmony linear accelerators (linacs) in Ukraine will complement the ...

Time October 25, 2023
News | Proton Therapy

October 23, 2023 — IBA, a world leader in particle accelerator technology and the world’s leading provider of proton ...

Time October 23, 2023
News | Radiopharmaceuticals and Tracers

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
News | Radiation Therapy

October 19, 2023 — The lung is one of the tissues most sensitive to radiation in the human body. People exposed to high ...

Time October 19, 2023
News | Radiopharmaceuticals and Tracers

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

Time October 18, 2023
Subscribe Now